AssetMark Inc
MED icon

AssetMark Inc’s Medifast MED Stock Holding History

AssetMark Inc’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-275
Closed -$28.5K – 1635
2023
Q1 		$28.5K Buy
275
+84
+44% +$9.31K ﹤0.01% 1142
2022
Q4 		$22K Buy
191
+35
+22% +$4.08K ﹤0.01% 1186
2022
Q3 		$17K Buy
156
+46
+42% +$6.59K ﹤0.01% 1157
2022
Q2 		$20K Buy
110
+61
+124% +$10.9K ﹤0.01% 1121
2022
Q1 		$8K Buy
+49
New +$9.24K ﹤0.01% 1220
2019
Q3 		– Sell
-6
Closed -$1K – 1376
2019
Q2 		$1K Buy
6
+1
+20% +$139 ﹤0.01% 1249
2019
Q1 		$1K Sell
5
-15
-75% -$1.9K ﹤0.01% 1259
2018
Q4 		$3K Sell
20
-12
-38% -$2.05K ﹤0.01% 1169
2018
Q3 		$7K Sell
32
-5
-14% -$1.01K ﹤0.01% 1108
2018
Q2 		$6K Sell
37
-2
-5% -$256 ﹤0.01% 1138
2018
Q1 		$4K Buy
39
+3
+8% +$224 ﹤0.01% 1185
2017
Q4 		$3K Buy
+36
New +$2.39K ﹤0.01% 1353
2017
Q1 		– Sell
-3
Closed – – 1371
2016
Q4 		$0 Buy
+3
New +$121 ﹤0.01% 1332

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AssetMark Inc's MED Position: Q2 2023 in Review

AssetMark Inc sold out of Medifast (MED) in Q2 2023, closing a stake of 275 shares — an estimated $28.5K sold.

AssetMark Inc first reported a position in MED in Q4 2016 and held it in 13 quarters. The position peaked at $28.5K in Q1 2023. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

  • AssetMark Inc reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
  • AssetMark Inc sold 275 Medifast shares in Q2 2023, an estimated $28.5K.
  • AssetMark Inc first reported a position in Medifast in Q4 2016 and held it in 13 quarters.
  • AssetMark Inc's Medifast position peaked at $28.5K in Q1 2023.
  • 236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on AssetMark Inc's 13F filing for Q2 2023, filed 11 Aug 2023.